BioNTech SE · NASDAQ:BNTX
BioNTech — Q3 2025 Earnings Presentation
25 slides from BioNTech's earnings presentation, Nov 3, 2025
Slide 1: 3rd Quarter 2025 Financial Results & Corporate Update
3 Quarter 2025 rd Financial Results & Corporate Update November 3rd, 2025
Slide 2: This Slide Presentation Includes Forward-Looking Statements
This Slide Presentation Includes Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/
Slide 3: Progress Highlights, Oncology Execution Update, Financial Update
1 Progress Highlights Uğur Şahin, Co-founder & Chief Executive Officer 2 Oncology Execution Update Özlem Türeci, Co-founder & Chief Medical Officer 3 Financial Update Ramón Zapata, Chief Financial Officer
Slide 4: 3rd Quarter 2025 Progress Highlights
3rd Quarter 2025 1 Progress Highlights Uğur Şahin, Co-founder & Chief Executive Officer
Slide 5: Translating Science into Survival: Building a Global Immunotherapy Powerhouse
Translating Science into Survival Building a Global Immunotherapy Powerhouse
Slide 6: Purpose-Built Pipeline To Enable Novel–Novel Combinations Across Solid Tumors
Purpose-Built Pipeline To Enable Novel–Novel Combinations Across Solid Tumors Novel mRNA cancer immunotherapies Next-Generation IO-backbone FixVac & iNeST1 Pumitamig2 Next generation of personalized cancer therapy targeting PD-L1/VEGF-A bispecific antibody tumor associated antigens and cancer mutati
Slide 7: 3Q 2025 Progress Towards Our Strategic Goals
3Q 2025 Progress Towards Our Strategic Goals Oncology Execution • Executing broad pan-tumor development plan led by registrational Phase 3 clinical trials in lung2 and breast cancer with first potential launches before the end of the decade Pumitamig1 • Progressed clinical mono-agent profiling of po
Slide 8: 3rd Quarter 2025 Oncology Execution Update
3rd Quarter 2025 2 Oncology Execution Update Özlem Türeci, Co-founder & Chief Medical Officer
Slide 9: Advancing Towards Commercial Stage in Oncology
Advancing Towards Commercial Stage in Oncology mRNA Cancer Trastuzumab Pumitamig1 Immunotherapies pamirtecan2 Aim to accelerate and expand Generating data that support and Advancing T-Pam2 towards BLA Pumitamig1 development in strategic inform our current development submission in EC and BC collabor
Slide 10: Pumitamig – Executing a Parallel Three-Wave Strategy to Build a Proprietary IO Franchise
Pumitamig – Executing a Parallel Three-Wave Strategy to Build a Proprietary IO Franchise Q3 actions advanced registrational readiness (dose, design, geography) and combination rationale, the two prerequisites for a durable backbone. Establish Expand Elevate Foundational Registrations Registrational
Slide 11: Establishing Pumitamig in Small Cell Lung Cancer
Establishing Pumitamig1 in Small Cell Lung Cancer Broad Presence Safety Profile Consistent Performance Unique Positioning Ph3 and Ph1/2 trials across 1L and Consistent and manageable safety Activity and safety confirmed in Designed to improve on current later lines; pan-tumor insights inform profile
Slide 12: ADC Single Agent Profiling to Inform Late-Stage Mono and Combo Development
ADC Single Agent Profiling to Inform Late-Stage Mono and Combo Development BNT324/DB-13111 (B7H3) Monotherapy in 2L+ SCLC and NSCLC BNT325/DB-13111 (TROP2) Monotherapy in 2L+ mTNBC Cheng et al. ESMO Asia 2024 57O Hamilton et al. ESMO 2025 #557P 75 cORR: 34.6 % nsqNSCLC (n=41) sqNSCLC (n=25) Overall
Slide 13: Clinical Trial Execution Across iNeST and FixVac Portfolios
Clinical Trial Execution Across iNeST and FixVac Portfolios Individualized Immunotherapy: iNeST FixVac Autogene cevumeran (BNT122/RO7198457)1 BNT1112 BNT113 BNT116 Adjuvant 1L R/R R/R 1L Multiple settings HPV16+ PD-L1 MIUC CRC PDAC Melanoma Solid tumors Melanoma NSCLC CPS ≥1 HNSCC Phase 2 Phase 2 Ph
Slide 14: BNT111 FixVac Phase 2 Data in PD-(L)1 Melanoma Yield Insights
BNT111 FixVac Phase 2 Data in PD-(L)1 Melanoma Yield Insights That Guide Further Development Key Inclusion Criteria Trial Design Key Findings • IIIc/IV melanoma, measurable BNT111 + Cemiplimab • A statistically significant improvement (ORR: 18.1%) of BNT111 + disease n=94 • ≥12 weeks of aPD-(L)1 cem
Slide 15: iNeST Phase 2 Data in 1L Melanoma Yield Insights That Support Current Development Focus
iNest1 Phase 2 Data in 1L Melanoma Yield Insights That Support Current Development Focus Trial Design Key Findings • Primary endpoint of progression free survival was not met. A numerical trend Pembrolizumab favoring the combination in overall survival at 12 and 24 months was observed 1L advanced R
Slide 16: Upcoming Data Guide Late-Stage Development Strategies
Upcoming Data Guide Late-Stage Development Strategies Establishing Pumitamig’s Foundation Pumitamig1 1L/2L TNBC Global Phase 2 Helps inform Phase 3 dose Validating our Broader ADC Platform BNT324/DB-13112 CC and PROC Phase 1/2 Informs contribution of components for combination BNT325/DB-13052 mTNBC
Slide 17: 3rd Quarter 2025 Financial Update
3rd Quarter 2025 3 Financial Update Ramón Zapata, Chief Financial Officer
Slide 18: Q3 and YTD Financial Results
Q3 and YTD Financial Results (in millions €, except per share data)1 Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Revenues 1,519 1,245 1,963 1,561 Cost of sales (148) (179) (309) (298) Research and development expenses (565) (550) (1,600) (1,642) Sales and mar
Slide 19: BioNTech Increases Revenues Guidance and Reduces Expenditures Guidance for FY 2025
BioNTech Increases Revenues Guidance and Reduces Expenditures Guidance for the Full Year 20251 FY Guidance March 2025 FY Guidance November 2025 Planned FY 2025 Revenues €1,700 – €2,200 m €2,600 – €2,800 m Revenues R&D expenses €2,600 – €2,800 m €2,000 – €2,200 m Planned FY 2025 Expenses and SG&A exp
Slide 20: Innovation Series R&D Day – Save the Date
Save the date Innovation Series R&D Day November 11, 2025 New York, NY U.S. Thank you!
Slide 21: Appendix
__. Appendix BIONT=Cr
Slide 22: Selected Pipeline Milestones in 2025 and Beyond
Selected Pipeline Milestones in 2025 and Beyond Program Indication 2025+ Milestone 1L/2L SCLC Global Phase 2 dose optimization data Next-Generation Pumitamig1 Immunomodulator 1L/2L TNBC Global Phase 2 dose optimization data Autogene cevumeran2 ctDNA+ adj. CRC Phase 2 update mRNA Cancer Immunotherapy
Slide 23: BioNTech's Oncology Pipeline – Phase 2 and Phase 3 Clinical Trials
BioNTech’s Oncology Pipeline – Phase 2 and Phase 3 Clinical Trials Phase 2 Phase 3 Pumitamig1 (PD-L1 x VEGF-A) Pumitamig1 (PD-L1 x VEGF-A) Pumitamig1 (PD-L1 x VEGF-A) 1L HCC + CTx6 2L NSCLC, + CTx 1L SCLC, + CTx Gotistobart4 (CTLA-4) Pumitamig1 (PD-L1 x VEGF-A) Pumitamig1 (PD-L1 x VEGF-A) PROC, + pe
Slide 24: BioNTech's Oncology Pipeline – Phase 1 and Phase 1/2 Clinical Trials
BioNTech’s Oncology Pipeline – Phase 1 and Phase 1/2 Clinical Trials Phase 1 Phase 1/2 BNT314/GEN10592 (EpCAMx4-1BB) Pumitamig1 (PD-L1 x VEGF-A) Pumitamig1 + BNT3213 combination Multiple solid tumors 1L TNBC6 1L HCC6 BNT317 Pumitamig1 (PD-L1 x VEGF-A) Multiple solid tumors Multiple solid tumors6 Pum
Slide 25: Abbreviation Directory
Abbreviation Directory nL nth line ESMO European Society for Medical Oncology PDAC Pancreatic ductal adenocarcinoma AACR American Association for Cancer Research FDA Food and Drug Administration PD-(L)1 Programmed cell death protein (ligand) 1 (bs)AB (bispecific) Antibody FixVac Fixed Antigen Vaccin